Skip to main content

Table 1 Demographics, clinical characteristics, and dose in critically ill patients receiving fluconazole, anidulafungin, and caspofungin therapy

From: Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study

  Fluconazole Anidulafungin Caspofungin
Number of patients 15 9 6
Age (years) 56 (44–82) 51 (41–66) 62 (58–72)
Weight (kg) 82 (80–90) 81 (76–92) 80 (75–85)
Male sex 11 (73) 7 (78) 5 (71)
Dose received (mg) 400 (200–400) 100 70 (loading dose)
Dose (mg/kg) 4.9 (2.3–5.0) NA NA
APACHE II score 22 (10–30) 18 (15–32) 22 (20–26)
SOFA score 7 (5–9) 6 (3–7) 3 (2–8)
Serum creatinine concentration (m Μ ) 88 (64–203) 119 (47–228) 258 (117–286)
Measured creatinine clearance (ml/min) 45 (14–103) 62 (15–113) NA
  1. Data are described as median [1st to 3rd quartile] or n (%).
  2. APACHE, Acute Physiology and Chronic Health Evaluation II score; SOFA, sequential Organ Failure Assessment; NA, insufficient patients with measured creatinine clearance/not applicable.